123 related articles for article (PubMed ID: 37824774)
1. ASSOCIATION OF miRNA EXPRESSION PATTERN WITH OUTCOME OF LETROZOLE THERAPY IN BREAST CANCER PATIENTS.
Pridko O; Borikun T; Rossylna O; Rusyn AV
Exp Oncol; 2023 Oct; 45(2):180-186. PubMed ID: 37824774
[TBL] [Abstract][Full Text] [Related]
2. EXPRESSION PATTERN OF miR-125b-2, -155, -221, AND -320a IS ASSOCIATED WITH RESPONSE OF BREAST CANCER PATIENTS TO TAMOXIFEN.
Pridko O; Borikun T; Rossylna O; Rishko M; Rusyn AV
Exp Oncol; 2022 Dec; 44(4):295-299. PubMed ID: 36811533
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
4. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
5. Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.
Campos-Parra AD; Mitznahuatl GC; Pedroza-Torres A; Romo RV; Reyes FIP; López-Urrutia E; Pérez-Plasencia C
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28574440
[TBL] [Abstract][Full Text] [Related]
6. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.
Wu X; Somlo G; Yu Y; Palomares MR; Li AX; Zhou W; Chow A; Yen Y; Rossi JJ; Gao H; Wang J; Yuan YC; Frankel P; Li S; Ashing-Giwa KT; Sun G; Wang Y; Smith R; Robinson K; Ren X; Wang SE
J Transl Med; 2012 Mar; 10():42. PubMed ID: 22400902
[TBL] [Abstract][Full Text] [Related]
7. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
8. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.
Erbes T; Hirschfeld M; Rücker G; Jaeger M; Boas J; Iborra S; Mayer S; Gitsch G; Stickeler E
BMC Cancer; 2015 Mar; 15():193. PubMed ID: 25886191
[TBL] [Abstract][Full Text] [Related]
11. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.
Wang H; Tan G; Dong L; Cheng L; Li K; Wang Z; Luo H
PLoS One; 2012; 7(4):e34210. PubMed ID: 22523546
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer.
Lukianova NY; Borikun TV; Chekhun VF
Exp Oncol; 2019 Sep; 41(3):242-247. PubMed ID: 31569928
[TBL] [Abstract][Full Text] [Related]
14. Candidate miRNAs in human breast cancer biomarkers: a systematic review.
Adhami M; Haghdoost AA; Sadeghi B; Malekpour Afshar R
Breast Cancer; 2018 Mar; 25(2):198-205. PubMed ID: 29101635
[TBL] [Abstract][Full Text] [Related]
15. Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer.
Eissa S; Matboli M; Shehata HH
Transl Res; 2015 Mar; 165(3):417-27. PubMed ID: 25445205
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
[TBL] [Abstract][Full Text] [Related]
17. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Selli C; Turnbull AK; Pearce DA; Li A; Fernando A; Wills J; Renshaw L; Thomas JS; Dixon JM; Sims AH
Breast Cancer Res; 2019 Jan; 21(1):2. PubMed ID: 30616553
[TBL] [Abstract][Full Text] [Related]
18. Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
Kalinina T; Kononchuk V; Alekseenok E; Obukhova D; Sidorov S; Strunkin D; Gulyaeva L
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33923732
[TBL] [Abstract][Full Text] [Related]
19. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
[TBL] [Abstract][Full Text] [Related]
20. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma.
D'Angelo E; Fassan M; Maretto I; Pucciarelli S; Zanon C; Digito M; Rugge M; Nitti D; Agostini M
Oncotarget; 2016 May; 7(19):28647-57. PubMed ID: 27081702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
